Annual Report 2022/23 - Continued solid earnings, but weaker growth amid challenging market conditions
ANNOUNCEMENT NO. 243
13 September 2023
Annual Report 2022/23 (1 July 2022 - 30 June 2023)
Continued solid earnings, but weaker growth amid challenging market conditions
ChemoMetec’s revenue for 2022/23 grew by 4% to DKK 442.3 million and operating profit (EBITDA) for 2022/23 was DKK 251.0 million, a 13% increase on 2021/22. In 2022/23, ChemoMetec continued developing the new Xcyto platform and the instruments XcytoMatic 40 and XcytoMatic 30. In addition to the XcytoMatic instruments, we expect to launch two more products, the NC-203 and the Xcyto 5, at the latest by end of the calender year 2024.
“Generally, the 2022/23 financial year was a challenging year, as rising interest rates and growing general uncertainty led to a reduced availability of new capital to customers in our most important market area, cell-based therapy. ChemoMetec made great efforts to adapt to these changing market conditions, and we succeeded in maintaining a positive earnings performance. At the end of the financial year, there were clear indications that the cell-based therapy market was stabilising – albeit at a lower level than in previous years.
We remain optimistic about the long-term potential of cell-based therapy, and consequently also ChemoMetec’s opportunities to create growth in this area. And with the upcoming launch of our new XcytoMatic products, we are entering another attractive market area – bioprocessing. The coming financial year will be a period of sustained macroeconomic and geopolitical uncertainty, however, which means that 2023/24 may well be a year of challenging growth conditions before we see a return of stronger growth prospects,” says Rasmus Kofoed, CEO.
- In the 2022/23 financial year, revenue grew by 4% to DKK 442.3 million measured in Danish kroner and declined by 1% measured at constant exchange rates.
- Sales of analytical instruments fell to DKK 179.0 million in 2022/23, a 17% decline measured in Danish kroner. Sales of instruments were particularly sensitive to the challenging investment climate in ChemoMetec’s market areas.
- Sales of consumables, including cassettes, slides, reagents and test kits, rose to DKK 174.4 million in 2022/23, an 18% increase measured in Danish kroner and a 13% increase measured at constant exchange rates.
- Sales of services, comprising service contracts, installations and various consulting services, rose to DKK 83.0 million in 2022/23, a 39% increase measured in Danish kroner and a 31% increase measured at constant exchange rates.
- Operating profit (EBITDA) amounted to DKK 251.0 million in 2022/23, a 13% increase on 2021/22. The EBITDA margin was 57%, up five percentage points on 2021/22.
- Profit for the year rose by DKK 19.2 million to DKK 178.7 million, a 12% year-on-year increase.
- Revenue and EBITDA for the year are in line with the most recent guidance announced on
8 February 2023.
- The Board of Directors proposes to the general meeting that a dividend of DKK 6.0 per share, equivalent to a total dividend payout of DKK 104.4 million, be distributed for the 2022/23 financial year. The proposal should be seen in the context of ChemoMetec’s strong financial position, and the planned investments in new facilities have also been taken into account.
- For 2023/24, ChemoMetec expects revenue in the range of DKK 400-435 million and EBITDA in the range of DKK 200-220 million.
The Company will host a conference call on Thursday, 14 September at 11:00 a.m.
Rasmus Kofoed, CEO, and Niels Høy Nielsen, CFO, will present the annual report for 2022/23. Their presentation will be followed by a Q&A session.
The conference call will be conducted in English.
Link to the conference call: https://chemometec.com/investor-relations/chemometec-fy-2022-23-conference-call/
Rasmus Kofoed, CEO
Tel.: (+45) 26 72 68 19
Niels Høy Nielsen, CFO
Tel.: (+45) 25 51 87 24
Attachments to this announcement
- Annual Report 2022/23 (English)
The annual report may also be downloaded from ChemoMetec’s websitewww.chemometec.com
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
LeddarTech and Prospector Capital Corp. Announce Effectiveness of Registration Statement and December 13, 2023 Extraordinary General Meeting to Approve Business Combination4.12.2023 23:30:00 CET | Press release
QUEBEC CITY, Dec. 04, 2023 (GLOBE NEWSWIRE) -- LeddarTech Inc.® (“LeddarTech” or the “Company”), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, and Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), a publicly traded special-purpose acquisition company led by former Qualcomm President Derek Aberle and chaired by former Qualcomm Vice Chairman Steve Altman, today announced that on December 4, 2023 the U.S. Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form F-4, as amended, filed by LeddarTech Holdings Inc. (“Newco”) in connection with the previously announced proposed business combination (the “Business Combination”). The filing can be viewed in its entirety on the SEC’s website at www.sec.gov. Prospector also commenced mailing the definitive proxy statement/prospectus on December 4, 2023, which was included in the Reg
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 20234.12.2023 22:30:00 CET | Press release
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.4.12.2023 22:16:59 CET | Press release
Aggregate gross proceeds of approximately €50.9 million (equivalent to approximately $53.8 million) received by NANOBIOTIX has increased to approximately €55.5 million (equivalent to approximately $58.7 million) extending its runway into mid’ 2025 PARIS and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces today the closing of the previously announced subscription by Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”) for 901,256 additional ordinary shares of the Company, in the form of restricted American Depositary Shares (“ADSs”), for an aggregate amount of $4.8 million, equivalent to €4.6 million1 (the “Remaining Placement Amount”, and the subscription transaction being the “Remaining Placement”), following the approval by the French Ministry of Economy of JJ
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH4.12.2023 22:05:00 CET | Press release
The DMC recommended to continue the clinical trial without modification of the protocol, based on the pre-planned review of safety dataThe safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeksThe DMC review remains consistent, confirming the good safety profile of lanifibranor Daix (France), Long Island City (New York, United States), December 4, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the positive recommendation from the third meeting of the Data Monitoring Committee (DMC) to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with NASH without modification to the trial protocol. The DMC
Standard Lithium to Participate in December Investor Conferences4.12.2023 22:04:35 CET | Press release
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced its participation in the following virtual December investor conferences: Event:Deustche Bank 8th Annual Virtual Lithium Battery Supply Chain ConferenceDate:December 6, 2023Panel:US Based Lithium Supply, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:15am PTEvent:Bank of America Securities Virtual 2023 Lithium and Battery Storage ConferenceDate:December 7, 2023Panel:Company Presentation, featuring Robert Mintak, CEO and Director of Standard Lithium, 7:45am – 8:30am PT Management will be hosting one-on-one meetings during the conferences. Interested investors should contact their Deutsche Bank or Bank of America representative or Standard Lithium Investor Relations at firstname.lastname@example.org. About Standard Lithium Ltd. St